Cargando…

Modified Zipper Method, a Promising Treatment Option in Severe Pediatric Immune-Mediated Neurologic Disorders

OBJECTIVE: To introduce and evaluate a modified version of the “zipper method”—a treatment strategy alternating intravenous immunoglobulin (IVIG) and plasma exchange (PLEX) first reported for 9 pediatric cases of Guillain-Barré syndrome in 2018—for treatment of severe immune-mediated neurologic diso...

Descripción completa

Detalles Bibliográficos
Autores principales: Nikolaus, Marc, Kühne, Fabienne, Tietze, Anna, Thumfart, Julia, Kempf, Caroline, Gratopp, Alexander, Knierim, Ellen, Bittigau, Petra, Kaindl, Angela M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160959/
https://www.ncbi.nlm.nih.gov/pubmed/35435761
http://dx.doi.org/10.1177/08830738221089476
_version_ 1784719382075670528
author Nikolaus, Marc
Kühne, Fabienne
Tietze, Anna
Thumfart, Julia
Kempf, Caroline
Gratopp, Alexander
Knierim, Ellen
Bittigau, Petra
Kaindl, Angela M.
author_facet Nikolaus, Marc
Kühne, Fabienne
Tietze, Anna
Thumfart, Julia
Kempf, Caroline
Gratopp, Alexander
Knierim, Ellen
Bittigau, Petra
Kaindl, Angela M.
author_sort Nikolaus, Marc
collection PubMed
description OBJECTIVE: To introduce and evaluate a modified version of the “zipper method”—a treatment strategy alternating intravenous immunoglobulin (IVIG) and plasma exchange (PLEX) first reported for 9 pediatric cases of Guillain-Barré syndrome in 2018—for treatment of severe immune-mediated neurologic disorders in children. METHODS: The modified zipper method comprised longer intervals between PLEX-IVIG cycles (48 hours instead of 24 hours), more cycles (7-10 instead of 5), a consistent plasma volume exchange (instead of the original multistep approach), and variable infusion times for IVIGs (4-8 hours). The modified zipper method was applied as an individual treatment approach once standard therapy failed. The follow-up ranged from 6 months to 2 years. Cases were analyzed retrospectively. Disease severity was mainly quantified by the Guillain-Barré syndrome disability score. RESULTS: Four children (9-15 years) with (1) Miller-Fisher syndrome, (2) Bickerstaff brainstem encephalitis, (3) common Guillain-Barré syndrome, and (4) severe acute disseminated encephalomyelitis were treated by the modified zipper method. Results for duration of mechanical ventilation (median of 12 days, interquartile range [IQR] 8-16), hospital stay (median of 23 days, IQR 22-24), and time to unaided walking (median of 22 days, IQR 21-37) outperformed previous studies with IVIG/PLEX alone or IVIG + PLEX combinations unlike the zipper method. CONCLUSION: The modified zipper method is associated with a low mortality, a short mechanical ventilation time, a short hospital stay, and an excellent outcome in children with severe Guillain-Barré syndrome or acute disseminated encephalomyelitis. Our regimen is streamlined for applicability. Results emphasize its robust effectiveness as an option for therapy escalation in severe neuroimmunologic diseases. Now, multicenter trials are needed to evaluate this novel treatment strategy.
format Online
Article
Text
id pubmed-9160959
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-91609592022-06-03 Modified Zipper Method, a Promising Treatment Option in Severe Pediatric Immune-Mediated Neurologic Disorders Nikolaus, Marc Kühne, Fabienne Tietze, Anna Thumfart, Julia Kempf, Caroline Gratopp, Alexander Knierim, Ellen Bittigau, Petra Kaindl, Angela M. J Child Neurol Original Articles OBJECTIVE: To introduce and evaluate a modified version of the “zipper method”—a treatment strategy alternating intravenous immunoglobulin (IVIG) and plasma exchange (PLEX) first reported for 9 pediatric cases of Guillain-Barré syndrome in 2018—for treatment of severe immune-mediated neurologic disorders in children. METHODS: The modified zipper method comprised longer intervals between PLEX-IVIG cycles (48 hours instead of 24 hours), more cycles (7-10 instead of 5), a consistent plasma volume exchange (instead of the original multistep approach), and variable infusion times for IVIGs (4-8 hours). The modified zipper method was applied as an individual treatment approach once standard therapy failed. The follow-up ranged from 6 months to 2 years. Cases were analyzed retrospectively. Disease severity was mainly quantified by the Guillain-Barré syndrome disability score. RESULTS: Four children (9-15 years) with (1) Miller-Fisher syndrome, (2) Bickerstaff brainstem encephalitis, (3) common Guillain-Barré syndrome, and (4) severe acute disseminated encephalomyelitis were treated by the modified zipper method. Results for duration of mechanical ventilation (median of 12 days, interquartile range [IQR] 8-16), hospital stay (median of 23 days, IQR 22-24), and time to unaided walking (median of 22 days, IQR 21-37) outperformed previous studies with IVIG/PLEX alone or IVIG + PLEX combinations unlike the zipper method. CONCLUSION: The modified zipper method is associated with a low mortality, a short mechanical ventilation time, a short hospital stay, and an excellent outcome in children with severe Guillain-Barré syndrome or acute disseminated encephalomyelitis. Our regimen is streamlined for applicability. Results emphasize its robust effectiveness as an option for therapy escalation in severe neuroimmunologic diseases. Now, multicenter trials are needed to evaluate this novel treatment strategy. SAGE Publications 2022-04-18 2022-05 /pmc/articles/PMC9160959/ /pubmed/35435761 http://dx.doi.org/10.1177/08830738221089476 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Articles
Nikolaus, Marc
Kühne, Fabienne
Tietze, Anna
Thumfart, Julia
Kempf, Caroline
Gratopp, Alexander
Knierim, Ellen
Bittigau, Petra
Kaindl, Angela M.
Modified Zipper Method, a Promising Treatment Option in Severe Pediatric Immune-Mediated Neurologic Disorders
title Modified Zipper Method, a Promising Treatment Option in Severe Pediatric Immune-Mediated Neurologic Disorders
title_full Modified Zipper Method, a Promising Treatment Option in Severe Pediatric Immune-Mediated Neurologic Disorders
title_fullStr Modified Zipper Method, a Promising Treatment Option in Severe Pediatric Immune-Mediated Neurologic Disorders
title_full_unstemmed Modified Zipper Method, a Promising Treatment Option in Severe Pediatric Immune-Mediated Neurologic Disorders
title_short Modified Zipper Method, a Promising Treatment Option in Severe Pediatric Immune-Mediated Neurologic Disorders
title_sort modified zipper method, a promising treatment option in severe pediatric immune-mediated neurologic disorders
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160959/
https://www.ncbi.nlm.nih.gov/pubmed/35435761
http://dx.doi.org/10.1177/08830738221089476
work_keys_str_mv AT nikolausmarc modifiedzippermethodapromisingtreatmentoptioninseverepediatricimmunemediatedneurologicdisorders
AT kuhnefabienne modifiedzippermethodapromisingtreatmentoptioninseverepediatricimmunemediatedneurologicdisorders
AT tietzeanna modifiedzippermethodapromisingtreatmentoptioninseverepediatricimmunemediatedneurologicdisorders
AT thumfartjulia modifiedzippermethodapromisingtreatmentoptioninseverepediatricimmunemediatedneurologicdisorders
AT kempfcaroline modifiedzippermethodapromisingtreatmentoptioninseverepediatricimmunemediatedneurologicdisorders
AT gratoppalexander modifiedzippermethodapromisingtreatmentoptioninseverepediatricimmunemediatedneurologicdisorders
AT knierimellen modifiedzippermethodapromisingtreatmentoptioninseverepediatricimmunemediatedneurologicdisorders
AT bittigaupetra modifiedzippermethodapromisingtreatmentoptioninseverepediatricimmunemediatedneurologicdisorders
AT kaindlangelam modifiedzippermethodapromisingtreatmentoptioninseverepediatricimmunemediatedneurologicdisorders